TherapeuticsMD, Inc. — Director's Dealing 2021

Aug 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-08-17

Reporting Person: Collins Cooper C. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	P	100000	$0.77	Acquired	336864	Direct
2021-08-18	Common Stock	P	900000	$0.72	Acquired	1236864	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.746 to $0.78 for an average weighted purchase price of $0.77. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.715 to $0.727 for an average weighted purchase price of $0.72. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.